II期临床试验-话题@MedSci

#II期临床试验#

174篇内容 | 3274人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1931473, encodeId=e43b19314e398, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=2019年国际血栓和止血学会：II期临床试验抗组织因子抑制剂单抗Concizumab对A/B型血友病患者安全有效, objectType=article, longId=175613, objectId=674d1e56136b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=674d1e56136b, replyNumber=0, likeNumber=68, createdTime=2019-07-31, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=674d1e56136b, moduleTitle=2019年国际血栓和止血学会：II期临床试验抗组织因子抑制剂单抗Concizumab对A/B型血友病患者安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=674d1e56136b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931468, encodeId=c26e1931468ff, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=第24届EHA大会：5F9联合利妥昔单抗治疗复发难治性非霍奇金淋巴瘤的Ib / II期临床试验, objectType=article, longId=168728, objectId=5792168e289d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5792168e289d, replyNumber=0, likeNumber=63, createdTime=2020-01-08, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5792168e289d, moduleTitle=第24届EHA大会：5F9联合利妥昔单抗治疗复发难治性非霍奇金淋巴瘤的Ib / II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5792168e289d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931459, encodeId=492019314591c, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=Mallinckrodt完成了StrataGraft再生皮肤组织的III期临床试验的全面注册, objectType=article, longId=164219, objectId=e04a16421946, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e04a16421946, replyNumber=0, likeNumber=60, createdTime=2020-03-26, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e04a16421946, moduleTitle=Mallinckrodt完成了StrataGraft再生皮肤组织的III期临床试验的全面注册, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e04a16421946)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931448, encodeId=89601931448a8, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=III期临床试验证明恩杂鲁胺与雄激素剥夺疗法（ADT）联合使用明显改善转移性前列腺癌的存活率, objectType=article, longId=160414, objectId=ea1416041497, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea1416041497, replyNumber=0, likeNumber=76, createdTime=2019-02-21, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea1416041497, moduleTitle=III期临床试验证明恩杂鲁胺与雄激素剥夺疗法（ADT）联合使用明显改善转移性前列腺癌的存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea1416041497)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931444, encodeId=0599193144446, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle="PANDA"登陆巴黎！康柏西普全球多中心III期临床试验欧洲区研究者大会召开, objectType=article, longId=156456, objectId=54b315645636, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54b315645636, replyNumber=0, likeNumber=0, createdTime=2019-03-19, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54b315645636, moduleTitle="PANDA"登陆巴黎！康柏西普全球多中心III期临床试验欧洲区研究者大会召开, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54b315645636)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931442, encodeId=c436193144204, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle="PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动, objectType=article, longId=156388, objectId=8ee71563888f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ee71563888f, replyNumber=0, likeNumber=58, createdTime=2019-09-30, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ee71563888f, moduleTitle="PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ee71563888f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931445, encodeId=577819314459b, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=Incyte宣布开展Ruxolitinib的III期临床试验, objectType=article, longId=156672, objectId=aeee1566e228, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aeee1566e228, replyNumber=0, likeNumber=67, createdTime=2019-04-02, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aeee1566e228, moduleTitle=Incyte宣布开展Ruxolitinib的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aeee1566e228)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931440, encodeId=fce1193144039, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=NEJM：免疫治疗在晚期三阴乳腺癌III期临床试验中成功！中位总生存期提高61.3%, objectType=article, longId=151769, objectId=5ffc151e69a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ffc151e69a2, replyNumber=0, likeNumber=69, createdTime=2019-03-27, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ffc151e69a2, moduleTitle=NEJM：免疫治疗在晚期三阴乳腺癌III期临床试验中成功！中位总生存期提高61.3%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ffc151e69a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931450, encodeId=03d81931450b9, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=默沙东将开展Keytruda治疗前列腺癌的3个III期临床试验, objectType=article, longId=160438, objectId=5b3116043863, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b3116043863, replyNumber=0, likeNumber=91, createdTime=2019-12-06, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b3116043863, moduleTitle=默沙东将开展Keytruda治疗前列腺癌的3个III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b3116043863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931454, encodeId=f41e19314542a, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=双重抗血小板疗法(替格瑞洛联合阿司匹林)在控制不良心血管事件的III期临床试验中大获成功, objectType=article, longId=161192, objectId=ee9f16119219, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee9f16119219, replyNumber=0, likeNumber=62, createdTime=2019-09-29, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee9f16119219, moduleTitle=双重抗血小板疗法(替格瑞洛联合阿司匹林)在控制不良心血管事件的III期临床试验中大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee9f16119219)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931453, encodeId=f8de19314530f, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=默克Keytruda治疗晚期肝癌的III期临床试验失败告终, objectType=article, longId=160650, objectId=909e1606500c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=909e1606500c, replyNumber=0, likeNumber=70, createdTime=2020-01-02, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=909e1606500c, moduleTitle=默克Keytruda治疗晚期肝癌的III期临床试验失败告终, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=909e1606500c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931464, encodeId=f897193146470, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=III期临床试验证实Fc融合凝血因子延长半衰期，可为血友病患者提供有效的围手术期止血, objectType=article, longId=165917, objectId=84ae16591e2f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84ae16591e2f, replyNumber=0, likeNumber=29, createdTime=2019-12-13, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84ae16591e2f, moduleTitle=III期临床试验证实Fc融合凝血因子延长半衰期，可为血友病患者提供有效的围手术期止血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84ae16591e2f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931437, encodeId=c1d7193143ec5, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=Vertex在III期临床试验中测试CF三联疗法, objectType=article, longId=136761, objectId=2419136e61db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2419136e61db, replyNumber=0, likeNumber=60, createdTime=2018-08-09, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2419136e61db, moduleTitle=Vertex在III期临床试验中测试CF三联疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2419136e61db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931452, encodeId=6a2b193145237, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=III期临床试验证实Keytruda联用阿西替尼显著降低晚期肾癌的死亡率, objectType=article, longId=160546, objectId=fa9316054665, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa9316054665, replyNumber=0, likeNumber=130, createdTime=2019-12-09, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa9316054665, moduleTitle=III期临床试验证实Keytruda联用阿西替尼显著降低晚期肾癌的死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa9316054665)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931443, encodeId=f95b19314437b, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle="PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动, objectType=article, longId=156414, objectId=bb9a156414cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb9a156414cc, replyNumber=0, likeNumber=44, createdTime=2019-07-22, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb9a156414cc, moduleTitle="PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb9a156414cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931451, encodeId=64371931451f2, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=FDA批准新型心血管支持液VBI-1进入II期临床试验, objectType=article, longId=160532, objectId=d280160532df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d280160532df, replyNumber=0, likeNumber=63, createdTime=2019-07-22, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d280160532df, moduleTitle=FDA批准新型心血管支持液VBI-1进入II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d280160532df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931439, encodeId=7e36193143976, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=III期临床试验显示：阿斯利康SCLT2抑制剂Farxiga显着降低II型糖尿病患者的心力衰竭和心血管死亡住院治疗率, objectType=article, longId=149631, objectId=33901496318e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33901496318e, replyNumber=0, likeNumber=63, createdTime=2019-06-25, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33901496318e, moduleTitle=III期临床试验显示：阿斯利康SCLT2抑制剂Farxiga显着降低II型糖尿病患者的心力衰竭和心血管死亡住院治疗率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33901496318e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931428, encodeId=ba2119314283d, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=EUR J Cancer：放疗联合卡培他滨和索拉非尼治疗晚期KRAS突变的直肠癌：I / II期临床试验（SAKK 41/08）, objectType=article, longId=124481, objectId=c81c12448125, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c81c12448125, replyNumber=0, likeNumber=44, createdTime=2018-05-27, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c81c12448125, moduleTitle=EUR J Cancer：放疗联合卡培他滨和索拉非尼治疗晚期KRAS突变的直肠癌：I / II期临床试验（SAKK 41/08）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c81c12448125)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931430, encodeId=747219314302d, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=EUR J Cancer：舒尼替尼治疗局部晚期或转移性、间变性甲状腺髓质癌的多中心II期临床试验, objectType=article, longId=124996, objectId=11e112499612, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11e112499612, replyNumber=0, likeNumber=52, createdTime=2018-12-03, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11e112499612, moduleTitle=EUR J Cancer：舒尼替尼治疗局部晚期或转移性、间变性甲状腺髓质癌的多中心II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11e112499612)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931433, encodeId=70bf19314337f, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=JAMA：idalopirdine治疗轻中度阿尔斯海默III期临床试验失败, objectType=article, longId=126123, objectId=8fa3126123fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fa3126123fa, replyNumber=0, likeNumber=57, createdTime=2018-08-18, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fa3126123fa, moduleTitle=JAMA：idalopirdine治疗轻中度阿尔斯海默III期临床试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fa3126123fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床试验

2020-05-29

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

2019年国际血栓和止血学会：II期临床试验抗组织因子抑制剂单抗Concizumab对A/B型血友病患者安全有效

2019-07-31

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

第24届EHA大会：5F9联合利妥昔单抗治疗复发难治性非霍奇金淋巴瘤的Ib / II期临床试验

2020-01-08

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

Mallinckrodt完成了StrataGraft再生皮肤组织的III期临床试验的全面注册

2020-03-26

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

III期临床试验证明恩杂鲁胺与雄激素剥夺疗法（ADT）联合使用明显改善转移性前列腺癌的存活率

2019-02-21

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

"PANDA"登陆巴黎！康柏西普全球多中心III期临床试验欧洲区研究者大会召开

2019-03-19

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

"PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动

2019-09-30

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

Incyte宣布开展Ruxolitinib的III期临床试验

2019-04-02

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

NEJM：免疫治疗在晚期三阴乳腺癌III期临床试验中成功！中位总生存期提高61.3%

2019-03-27

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

默沙东将开展Keytruda治疗前列腺癌的3个III期临床试验

2019-12-06

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

双重抗血小板疗法(替格瑞洛联合阿司匹林)在控制不良心血管事件的III期临床试验中大获成功

2019-09-29

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

默克Keytruda治疗晚期肝癌的III期临床试验失败告终

2020-01-02

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

III期临床试验证实Fc融合凝血因子延长半衰期，可为血友病患者提供有效的围手术期止血

2019-12-13

zhouqu_8 (审核中...)

前往app查看评论内容

#II期临床试验#

Vertex在III期临床试验中测试CF三联疗法

2018-08-09

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

III期临床试验证实Keytruda联用阿西替尼显著降低晚期肾癌的死亡率

2019-12-09

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

"PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动

2019-07-22

医者仁心 (审核中...)

前往app查看评论内容

#II期临床试验#

FDA批准新型心血管支持液VBI-1进入II期临床试验

2019-07-22

zhouqu_8 (审核中...)

前往app查看评论内容

#II期临床试验#

III期临床试验显示：阿斯利康SCLT2抑制剂Farxiga显着降低II型糖尿病患者的心力衰竭和心血管死亡住院治疗率

2019-06-25

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

EUR J Cancer：放疗联合卡培他滨和索拉非尼治疗晚期KRAS突变的直肠癌：I / II期临床试验（SAKK 41/08）

2018-05-27

zhouqu_8 (审核中...)

前往app查看评论内容

#II期临床试验#

EUR J Cancer：舒尼替尼治疗局部晚期或转移性、间变性甲状腺髓质癌的多中心II期临床试验

2018-12-03

zhouqu_8 (审核中...)

前往app查看评论内容

#II期临床试验#

JAMA：idalopirdine治疗轻中度阿尔斯海默III期临床试验失败

2018-08-18

科室
- - 订阅+
  - 更多科室
工具
服务